evidence: Compared with placebo, risedronate 2.5 mg or 5.0 mg once daily reduced the risk of hip fracture by 46% (relative risk [RR] 0.54; 95% CI 0.32–0.91; P = 0.019)
intervention: Risedronate 5 mg
comparator: Placebo
outcome: Hip fracture frequency